FIELD: medicine.
SUBSTANCE: invention relates to a method for the treatment of pulmonary arterial hypertension. A combination of therapeutically effective amounts of a tyrosine kinase inhibitor, a phosphodiesterase type 5 inhibitor (PDEV) selected from sildenafil, tadalafil or vardenafil, and an endothelin receptor antagonist, which is ambrisentan, is used.
EFFECT: combined treatment increased the expression of the PDGFB gene in the lungs by approximately 70%, reduced systolic pressure in the right ventricle by 47%, and reduced right ventricular hypertrophy by 27%.
17 cl, 21 dwg, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MMPL3 INHIBITORS, COMPOSITIONS BASED ON THEM AND WAYS OF THEIR APPLICATION | 2019 |
|
RU2795229C2 |
| BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR TREATING CANCER | 2015 |
|
RU2741914C2 |
| 2,5-DISUBSTITUTED ARYLSULPHONAMIDE CCR3 ANTAGONISTS | 2010 |
|
RU2532515C2 |
| PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | 2012 |
|
RU2677292C2 |
| (ALPHA-SUBSTITUTED ARALKYLAMINO- AND HETEROARYLALKYLAMINO)PYRIMIDINYL- AND 1,3,5-TRIAZINYLBENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF IN TREATING PROLIFERATIVE DISEASES | 2012 |
|
RU2608742C2 |
| ARYLSULPHONAMIDE CCR3 ANTAGONISTS | 2010 |
|
RU2539591C2 |
| AZAPEPTIDE DERIVATIVES | 2008 |
|
RU2448958C2 |
| SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | 2012 |
|
RU2566083C2 |
| METHODS OF PRODUCING TRICYCLIC SERD COMPOUNDS HAVING SUBSTITUTED PHENYL OR PYRIDINYL MOIETY | 2021 |
|
RU2818455C1 |
| DEUTERIZED BENZIMIDAZOLE COMPOUND AND ITS MEDICAL USE | 2018 |
|
RU2804319C2 |
